We are HEPHAISTOS-Pharma
A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.
One need, one mission :
Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.
Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.
International experts & experimented operational team
Pr. Charles DUMONTET, MD PhD,
Deputy Director at Lyon Cancerology Research Center, Pr. of Hematology at the University of Lyon,
Pr. Jean-Yves BLAY, MD PhD,
Sarcoma & GIST KOL
Director at Centre Léon BERARD, President of the European Organisation for Research and Treatment of Cancer,
Dr. Nathalie GARÇON, PharmD PhD,
Vaccine Immunostimulant KOL
CEO/CSO BIOASTER, Former GSK Vaccines Vice President,
Dr. Pierre DESMONS, PhD
Pharma Manufacturing KOL
Owner at DESMONS Consulting, Former GSK Vaccines Vice President
Turning cold tumors into hot tumors
Only 10% of patients are completely cured with immunotherapies
Clinicians need innovatives immuno-stimulators to turn cold tumors into hot tumors and improve the patients’ cure rate
Innovation & advantages
Mechanism of Action
Mechanism of Action (MoA)
will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.
will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.
By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.
Clusters & Partners
HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund
HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.
HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937
HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.